Last updated: September 5, 2026
Cholic acid is a rare-disease bile acid replacement therapy marketed in the United States as Cholbam and in Europe as Orphacol. The market is small, specialist-driven, and protected more by orphan-disease economics, physician familiarity, diagnostic complexity, and manufacturing requirements than by broad patent exclusivity. Mirum Pharmaceuticals acquired U.S. rights to Cholbam and Chenodal from Leadiant Biosciences in 2022. Cholbam and Chenodal are reported together in Mirum’s financial statements, preventing a fully transparent standalone revenue analysis.[1]
What is cholic acid used to treat?
Cholic acid is a naturally occurring primary bile acid used as replacement therapy in disorders that impair endogenous bile acid synthesis or peroxisomal function.
Cholbam FDA indications
The U.S. Food and Drug Administration approved Cholbam capsules in 2015 for:
- Bile acid synthesis disorders caused by single-enzyme defects
- Adjunctive treatment of peroxisomal disorders, including Zellweger spectrum disorders
The product is used in patients who lack adequate endogenous bile acid production. Treatment can improve bile flow, reduce toxic bile acid accumulation, and support fat absorption and nutritional status.[2]
Orphacol European indication
Orphacol is authorized in the European Union for inborn primary bile acid synthesis disorders caused by 3-beta-hydroxy-Delta-5-C27-steroid oxidoreductase deficiency or Delta-4-3-oxosteroid-5-beta-reductase deficiency. The European product is marketed by Laboratoires CTRS, which was acquired by Advanz Pharma in 2021.[3]
The U.S. and European products address overlapping rare metabolic conditions, but their regulatory labels, commercial owners, reimbursement structures, and patent positions differ.
Who markets cholic acid products?
| Product |
Active ingredient |
Principal market |
Commercial company |
Regulatory status |
| Cholbam |
Cholic acid |
United States |
Mirum Pharmaceuticals |
FDA-approved orphan drug |
| Orphacol |
Cholic acid |
European Union and selected international markets |
Advanz Pharma / Laboratoires CTRS |
EU-authorized orphan medicine |
| Chenodal |
Chenodeoxycholic acid |
United States |
Mirum Pharmaceuticals |
Separate bile acid product, not cholic acid |
Mirum acquired U.S. rights to Cholbam and Chenodal from Leadiant in 2022. The transaction expanded Mirum’s rare-disease portfolio and added commercial products with established reimbursement and specialist-prescriber infrastructure.[4]
Cholbam is distributed through specialty-pharmacy and patient-support channels. Its customer base is concentrated among metabolic disease centers, pediatric gastroenterologists, hepatologists, and specialists treating peroxisomal disorders.
When does cholic acid lose exclusivity?
Cholbam’s seven-year U.S. orphan-drug exclusivity began with FDA approval in February 2015 and expired in February 2022. Orphan exclusivity prevented FDA approval of the same drug for the same indication during that period, subject to statutory exceptions.[2]
| Exclusivity or IP event |
Date or status |
| Cholbam FDA approval |
February 2015 |
| U.S. orphan-drug exclusivity |
Expired February 2022 |
| U.S. pediatric extension |
No broadly identified extension that materially changes the commercial analysis |
| Small-molecule regulatory pathway |
ANDA or 505(b)(2), depending on product and labeling strategy |
| Biosimilar pathway |
Not applicable |
| Commercial patent protection |
Requires product-specific Orange Book and patent-file review |
Expiration of orphan exclusivity did not automatically create immediate generic competition. A generic applicant still must address formulation, bioequivalence, labeling, manufacturing, distribution, and any enforceable listed patents.
What patents protect Cholbam and cholic acid formulations?
The commercial protection for cholic acid is narrower than the protection for a newly discovered chemical entity. Cholic acid is an established natural molecule, so composition-of-matter protection is not the principal barrier.
Potential protection has centered on:
- Methods of treating bile acid synthesis disorders
- Patient selection and disease-specific use
- Dosing regimens
- Formulation and capsule characteristics
- Manufacturing and purification processes
- Regulatory exclusivity for rare pediatric and metabolic indications
The Orange Book status must be assessed at the NDA level, including listed patents, expiration dates, pediatric extensions, and whether any patent has been delisted or expired. Cholbam’s key commercial moat is not a long-lived molecule patent. It is the combination of orphan development history, clinical familiarity, limited patient numbers, diagnostic complexity, and specialized distribution.
How strong is the patent estate for cholic acid?
The patent estate is moderate to weak when measured against a conventional branded small-molecule product with an unexpired composition-of-matter patent. It is stronger when measured against the practical barriers facing a generic entrant.
| Protection category |
Relative strength |
Commercial effect |
| Chemical composition |
Low |
Cholic acid is an established natural bile acid |
| Orphan exclusivity |
High during exclusivity period; expired in 2022 |
Historically delayed same-indication competition |
| Method-of-use patents |
Moderate if enforceable and clinically specific |
Can complicate labeling and litigation strategy |
| Formulation patents |
Moderate |
May delay substitution if technically differentiated |
| Manufacturing know-how |
Moderate to high |
Relevant to purity, specifications, scale, and regulatory consistency |
| Patient-support infrastructure |
High in a small market |
Raises switching and launch costs |
| Diagnostic and clinical barriers |
High |
Limits rapid volume expansion by new entrants |
What is the Orange Book status of Cholbam?
Cholbam is an FDA-approved small-molecule prescription drug listed under NDA 205750. The commercial significance of any Orange Book listing depends on whether patents remain active and whether they cover the approved product, an approved method of use, or a formulation.
A generic applicant could face three principal pathways:
- File a Paragraph III certification and wait for patent expiration.
- File a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed.
- Pursue a 505(b)(2) application with a differentiated formulation, indication, or clinical strategy.
The absence of active composition-of-matter protection means a credible generic strategy could focus on product equivalence, manufacturing economics, and regulatory timing rather than overcoming a fundamental molecule patent.
Which companies are challenging cholic acid exclusivity?
No major publicly disclosed Paragraph IV litigation campaign has materially altered the U.S. Cholbam market in the available public record. The competitive threat is more likely to emerge from:
- Generic cholic acid capsule manufacturers
- 505(b)(2) applicants
- Compounded or hospital-prepared alternatives in limited settings
- Alternative bile acid therapies used off label
- International suppliers seeking U.S. market entry
The small addressable population reduces the expected return from expensive patent litigation. A generic company must obtain reliable patient volume before investing in development, ANDA preparation, launch inventory, pharmacovigilance, and specialty distribution.
What generic entry risks exist for Cholbam?
Generic entry risk is real but likely to develop gradually rather than through rapid substitution.
Regulatory risk
Cholic acid products may require close attention to:
- Capsule strength and dissolution
- Impurity and degradation profiles
- Bioequivalence methodology
- Food-effect considerations
- Pediatric dosing
- Labeling for separate metabolic disorders
- Manufacturing consistency for a natural or highly specialized active ingredient
An ANDA applicant may face difficulty proving equivalence if the reference product has unusual absorption characteristics or if FDA requires clinically relevant pharmacodynamic evidence.
Commercial risk
The market has several characteristics that reduce the immediate attractiveness of generic entry:
- Very small patient population
- High dependence on specialist diagnosis
- Low prevalence of eligible disorders
- Need for prior authorization
- Concentrated specialty distribution
- High consequences of treatment interruption
- Limited economies of scale
A generic could still pressure pricing if it secures payer substitution, but volume growth would be constrained by disease prevalence.
Launch scenarios
| Scenario |
Timing |
Likely market effect |
| No approved generic |
Near term |
Branded pricing remains stable, subject to payer pressure |
| Single generic entrant |
Medium term |
Selective discounts and contracting pressure |
| Multiple generic entrants |
Longer term |
Greater price erosion and potential automatic substitution |
| 505(b)(2) competitor |
Medium term |
May compete through formulation, dosing, or distribution |
| Compounding expansion |
Limited |
Localized substitution, with quality and regulatory constraints |
What is the financial trajectory for cholic acid?
Cholic acid is commercially important to Mirum but is not the company’s primary growth engine. Mirum reports Cholbam and Chenodal revenue together, so public disclosures do not provide a clean Cholbam-only revenue history.[1]
The financial trajectory has four stages:
1. Leadiant commercialization
Leadiant established Cholbam as a high-value orphan product after the 2015 FDA approval. The market depended on a small number of diagnosed patients, specialty reimbursement, and high annual treatment costs. Revenue growth was driven more by diagnosis and patient identification than by broad prescription expansion.
2. Orphan exclusivity period
From 2015 through early 2022, orphan exclusivity reduced the risk of same-indication competition. This allowed the commercial owner to maintain premium pricing while building specialist relationships and reimbursement processes.
3. Mirum acquisition
Mirum acquired U.S. rights to Cholbam and Chenodal in 2022. The transaction gave Mirum an established commercial platform and a source of revenue outside its lead product, Livmarli. It also created cross-selling and operational efficiencies in rare hepatology and metabolic diseases.[4]
4. Post-exclusivity maturity
The post-2022 market is mature rather than high-growth. Revenue is likely to depend on:
- Retention of existing patients
- Earlier diagnosis
- Expansion of treated peroxisomal-disorder patients
- Reimbursement continuity
- Price management
- Protection against generic or 505(b)(2) entry
- Manufacturing reliability
Cholbam and Chenodal are financially smaller than Livmarli within Mirum’s portfolio. Their value is strategic: they provide recurring rare-disease revenue, commercial infrastructure, and relationships with physicians who treat liver and metabolic disorders.
How does cholic acid compare with Chenodal?
Cholbam and Chenodal are both bile acid products marketed by Mirum, but they have different active ingredients and clinical uses.
| Attribute |
Cholbam |
Chenodal |
| Active ingredient |
Cholic acid |
Chenodeoxycholic acid |
| Main clinical role |
Bile acid synthesis and peroxisomal disorders |
Selected bile acid and cholesterol-related disorders |
| FDA approval framework |
Orphan metabolic indications |
Separate NDA and indication structure |
| Primary prescribers |
Metabolic specialists, pediatric gastroenterologists, hepatologists |
Hepatologists and specialists |
| Competitive risk |
Generic cholic acid and 505(b)(2) products |
Generic or alternative bile acid products |
| Financial reporting |
Reported with Chenodal by Mirum |
Reported with Cholbam by Mirum |
The products share infrastructure but are not interchangeable. A generic Chenodal entrant would not directly replace Cholbam, and vice versa.
What manufacturing and intellectual-property barriers affect cholic acid?
Manufacturing is a meaningful barrier even without strong composition patents. A commercial product must meet pharmaceutical-grade specifications for identity, purity, potency, impurities, capsule performance, and batch consistency.
Potential manufacturing risks include:
- Dependence on qualified active pharmaceutical ingredient suppliers
- Limited scale requirements
- Validation of impurity controls
- Product stability and packaging
- Specialized pediatric dosage requirements
- Regulatory scrutiny of supply-chain changes
These factors can deter small generic manufacturers. They also create an opportunity for a well-capitalized entrant with established rare-disease distribution and regulatory expertise.
What is the competitive outlook for cholic acid?
The market outlook is stable but limited in scale.
Demand drivers
- Improved diagnosis of inherited bile acid synthesis disorders
- Expansion of metabolic testing
- Greater recognition of peroxisomal disorders
- Long-term treatment requirements
- Specialist adoption of bile acid replacement therapy
Demand constraints
- Extremely low disease prevalence
- Delayed diagnosis
- Limited clinical trial populations
- Reimbursement hurdles
- Lack of broad primary-care prescribing
- Potential generic price erosion
Cholic acid is unlikely to become a mass-market product. Its commercial value depends on durable treatment of a narrow patient population and preservation of reimbursement economics.
What patent litigation and settlement risks affect cholic acid?
No major public settlement has reshaped the U.S. Cholbam market in the available record. The most likely litigation trigger would be an ANDA Paragraph IV filing directed at an unexpired formulation or method-of-use patent.
A settlement could include:
- An agreed generic launch date
- A license with royalties
- A limited authorized-generic arrangement
- Restrictions on indications or labeling
- Supply or distribution terms
The economic value of litigation would depend on remaining patent life, the size of the diagnosed population, and whether the generic could obtain automatic substitution.
Key Takeaways
- Cholbam is the principal U.S. cholic acid product; Orphacol is the principal European product.
- Cholbam received FDA approval in February 2015, and its seven-year orphan exclusivity expired in February 2022.
- The product does not rely primarily on a durable composition-of-matter patent.
- Method-of-use, formulation, manufacturing, and regulatory barriers remain relevant.
- Mirum acquired U.S. rights to Cholbam and Chenodal in 2022.
- Mirum reports the two products together, so standalone Cholbam revenue is not publicly transparent.
- Cholic acid is a mature, specialist-driven rare-disease market with limited volume growth.
- Generic entry is commercially possible but constrained by small patient numbers, specialty distribution, reimbursement complexity, and manufacturing requirements.
- Biosimilar risk is not applicable because cholic acid is a small-molecule drug.
- The product’s strategic value is recurring rare-disease revenue and commercial infrastructure rather than high-volume growth.
FAQs
Is cholic acid a biologic drug?
No. Cholic acid is a small-molecule bile acid. A biosimilar pathway does not apply.
Is Cholbam interchangeable with Orphacol?
No automatic interchangeability should be assumed. The products contain the same active ingredient but are approved under different regulatory systems and may have different labeling, dosage forms, specifications, and distribution controls.
Can a generic company launch cholic acid after orphan exclusivity expired?
Yes, in principle. The applicant must still satisfy FDA requirements and address any unexpired patents, formulation issues, labeling constraints, and manufacturing standards.
Does cholic acid have a composition-of-matter patent?
Commercial protection is not principally based on a new-molecule composition patent because cholic acid is an established natural bile acid. Product-specific formulation, method-of-use, and manufacturing patents may still affect entry.
What is the largest financial risk for Cholbam?
The largest risk is loss of pricing power after orphan exclusivity, particularly if a generic or 505(b)(2) competitor achieves FDA approval and payer-preferred status.
References
-
Mirum Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934: Form 10-K for fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2015). FDA approves Cholbam to treat rare disorders of bile acid synthesis. https://www.fda.gov
-
European Medicines Agency. (2013). Orphacol: EPAR - product information. https://www.ema.europa.eu
-
Mirum Pharmaceuticals, Inc. (2022). Mirum Pharmaceuticals acquires rights to Cholbam and Chenodal from Leadiant Biosciences. Company announcement.
